C-type natriuretic peptide/guanylyl cyclase-B (GC-B) system attenuates proliferation of rhabdomyosarcoma in combination with sildenafil: A novel anticancer therapy

Masahiro Zenitani,Kenji Kangawa,Hiroshi Hosoda,Takashi Nojiri,Toru Kimura,Shuichiro Uehara,Hiroomi Okuyama,Mikiya Miyazato,Koichi Miura

doi:10.1186/2050-6511-16-s1-a103

Abstract

Background/purpose Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Since patients with high-risk RMS have limited treatment options and a poor prognosis, and late complications including growth disturbance and secondary cancer induced by chemotherapy or radiation therapy are essential problems, novel therapies are urgently needed. C-type natriuretic peptide (CNP) has physiological activity mainly for mesenchymal cells to inhibit cell proliferation. We hypothesized that CNP attenuates proliferation of human RMS, a malignant mesenchymal tumor and provide rationale for using CNP to treat RMS.

Highlights

Background/purpose Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children
Experimental design Gene expression of guanylyl cyclase B (GC-B), receptor of the C-type natriuretic peptide (CNP) in rhabdomyosarcoma clinical samples and cell lines was assessed by using quantitative polymerase chain reaction
To ascertain biological activity of CNP in RMS cells, cyclic guanosine monophosphate, the second messenger molecule which is produced by the activation of GC-B and serves as the major signaling molecule was measured following addition of CNP

Summary

Introduction

C-type natriuretic peptide/guanylyl cyclase-B (GC-B) system attenuates proliferation of rhabdomyosarcoma in combination with sildenafil: A novel anticancer therapy Background/purpose Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. C-type natriuretic peptide (CNP) has physiological activity mainly for mesenchymal cells to inhibit cell proliferation.

Results

Conclusion